Comparative effectiveness and personalized medicine: Evolving together or apart?

Health Affairs

Volumn 29, Issue 10, 2010, Pages 1783-1787

  Epstein, Robert ^a   Russell Teagarden, J ^a  

^a Medco Research Institute LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST CONTROL; HEALTH CARE QUALITY; HUMAN; PERSONALIZED MEDICINE; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; COST CONTROL; HUMANS; INDIVIDUALIZED MEDICINE; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 79952115549     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0642     Document Type: Article

References (25)

1. Brown SR. Scurvy: how a surgeon, a mariner, and a gentleman solved the greatest medical mystery of the age of sail. New York (NY): St. Martin's Press; 2003.
2. Morabia A. P.C.A. Louis and the birth of clinical epidemiology. J Clin Epidemiol. 1996:49;1327-33.
3. AcademyHealth. A first look at the volume and cost of comparative effectiveness research in the United States-June 2009 [Internet]. Washington (DC): AcademyHealth; 2009 Jun [cited 2010 Aug 16]. Available from: http://www.academyhealth.org/files/FileDownloads/AH_Monograph_09FINAL7.pdf
4. Hochman M, McCormick D. Characteristics of comparative effectiveness studies of medications. JAMA. 2010:3030(10);951-8.
5. Steinbrook R. Health care and the American Recovery and Reinvestment Act. N Engl J Med. 2009:360;1057-60.
6. Pfizer. Prescribing information, Selzentry [Internet]. New York (NY): Pfizer Labs; 2010 May [cited 2010 Sep 20]. Available from: http://www.viivhealthcare.com/products/~/media/Files/G/GlaxoSmithKline-Plc/Attachments/pdfs/products/selzentry_maraviroc_tablets_5May2010.pdf
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
8. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008;29:456-8.
9. Kaufer D, Gandy S. APOE (epsilon)4 and bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology. 2009;73:2052-3.
10. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.
11. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-75.
12. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-58.
13. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprozole, and rabeprezole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-7.
14. Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30:787-96.
15. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8.
16. Pezalla E, Day D, Pulliadath I. Initial assessment of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038-9.
17. Bristol-Myers/Squibb and Sanofi Pharmaceuticals Partnership. Plavix prescribing information [Internet]. Bridgewater (NJ): Bristol-Myers/ Squibb; 2010 Mar 31 [cited 2010 Aug 16]. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020839s042lbl.pdf
18. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med. 2010;61:63-75.
19. Wadelius M, Chen LY, Downes K, Ghori K, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-70.
20. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106:135-40.
21. Gage BF, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-31.
22. Centers for Medicare and Medicaid Services. Pharmacogenomic testing for warfarin response [Internet]. Baltimore (MD): CMS; 2009 Dec 18 [cited 16 Aug 2010]. Available from: http://www.cms.hhs.gov/Transmittals/Downloads/R111NCD.pdf
23. Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am J Health-Syst Pharm. 2009;66:625-37.
24. Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
25. Woodcock J, Lesko L. Pharmacogenetics- tailoring treatment for the outliers. N Engl J Med. 2009;360: 811-3.